Skip to main content
. 2018 Nov 14;119(11):1367–1373. doi: 10.1038/s41416-018-0285-5

Fig. 2.

Fig. 2

Disease-free survival curves. The test cohort (a), the validation cohort (b), the combined cohorts (c), and all patients with mismatch repair-deficient (dMMR/microsatelite instable (MSI)) tumours (d). Blue represents CDX2-positive, yellow CDX2-moderate, and grey CDX2-negative tumours